Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMISation of pEripheral Lung Stereotactic Ablative Body Radiotherapy, a Prospective Independent Evaluation of 3 Fraction and 5 Fraction SABR Regimens (OPTIMISE Lung SABR)

NCT07777614 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT07777614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMISation of pEripheral Lung Stereotactic Ablative Body Radiotherapy, a Prospective Independent Evaluation of 3 Fraction and 5 Fraction SABR Regimens (OPTIMISE Lung SABR)
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2035
Enrollment
208 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer